Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    77
    ...
ATC Name B/G Ingredients Dosage Form Price
A10BD20 SYNJARDY B Empagliflozin - 12.5mg, Metformin HCl - 850mg 12.5mg/850mg Tablet, film coated 3,287,711 L.L
A10BX16 MOUNJARO KWIKPEN B Tirzepatide - 12.5mg/dose 12.5mg/dose Injectable solution 39,601,065 L.L
B01AC27 UPTRAVI B Selexipag - 1200mcg 1200mcg Tablet, film coated 275,097,581 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution 375,054,619 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution 375,054,619 L.L
H01BA02 MINIRIN MELT B Desmopressin - 120mcg 120mcg Tablet, Oral lyophilisate 4,970,873 L.L
M05BX04 XGEVA BioTech Denosumab - 120mg 120mg Injectable solution 33,545,669 L.L
L02BX02 FIRMAGON B Degarelix (acetate) - 120mg 120mg Injectable powder for solution+diluent 24,325,802 L.L
A08AB01 XENICAL B Orlistat - 120mg 120mg Capsule 4,036,903 L.L
A08AB01 ELIZA 120 G Orlistat - 120mg 120mg Capsule 1,167,223 L.L
A08AB01 ELIZASLIM 120 G Orlistat - 120mg 120mg Capsule 1,167,223 L.L
A08AB01 LESSFAT G Orlistat - 120mg 120mg Capsule 391,634 L.L
A08AB01 ONLEFIT G Orlistat - 120mg 120mg Capsule 1,537,356 L.L
A08AB01 ORLISTAT G Orlistat - 120mg 120mg Capsule, hard 847,965 L.L
A08AB01 ORLISTAT-SIGMA G Orlistat - 120mg 120mg Capsule 847,965 L.L
A08AB01 ORLY SLIM G Orlistat - 120mg 120mg Capsule 1,174,518 L.L
A08AB01 UNI-CAL G Orlistat - 120mg 120mg Capsule 1,174,518 L.L
R06AX26 EXOFEN G Fexofenadine HCl - 120mg 120mg Tablet, film coated 287,582 L.L
R06AX26 FENADEX 120 G Fexofenadine HCl - 120mg 120mg Tablet, film coated 295,645 L.L
M01AH05 ARCOXIA B Etoricoxib - 120mg 120mg Tablet, film coated 603,385 L.L
M01AH05 ARTRIX 120 G Etoricoxib - 120mg 120mg Tablet, film coated 511,940 L.L
H01CB03 SOMATULINE AUTOGEL B Lanreotide (acetate) - 120mg 120mg Injectable solution 57,492,826 L.L
M01AH05 CLINTON G Etoricoxib - 120mg 120mg Tablet, film coated 362,837 L.L
M01AH05 CONSORT G Etoricoxib - 120mg 120mg Tablet, film coated 309,084 L.L
M01AH05 COXIFLAM G Etoricoxib - 120mg 120mg Tablet, film coated 398,033 L.L
M01AH05 ETOXA G Etoricoxib - 120mg 120mg Tablet, film coated 398,033 L.L
M01AH05 ETOXIB G Etoricoxib - 120mg 120mg Tablet, film coated 425,998 L.L
M01AH05 JOSWE COXIT 120 G Etoricoxib - 120mg 120mg Tablet, film coated 517,379 L.L
N05AE05 LAROZA G Lurasidone - 120mg 120mg Tablet, film coated 5,548,726 L.L
    ...
    77
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025